Full text PDF - International Policy Network

More documents

Recommendations

Info

Corruption in public health 125 Ghana 2000 World Bank, 2000d Hungary 2002 Gaal, 2002 India 2002 Transparency International, 2002 Indonesia 2001 Partnership for Governance Reform, 2002 Khazakhstan 2001 World Bank, 2001c Kosovo 2000 LSMS Survey Krygyz 2001 Falkingham, 2002 Kyrgyz 2001 LSMS Survey Latvia 1998 Anderson, 1998 Macedonia 2002 Vitosha, 2002 Madagascar 2001 Tranparency International, 2003 Moldova 2000 Carasciuc, 2001 Moldova 2002 Stempovscaia, 2002 Morroco 2001 Tranparency International, 2003 Nepal 2002 Transparency International, 2002 Pakistan 2002 Transparency International, 2002 Paraguay 1999 World Bank, 2000c Peru 2001 World Bank, 2001 Poland 1998 Chawla, Berman & Kawiorska, 2001 Romania 2000 World Bank, 2001d Romania 2002 FBS Russia 2002 Shishkin (2003) Senegal 2001 Tranparency International, 2003 Serbia 2002 Vitosha, 2002 Slovakia 2000 Anderson, 2000 Sri Lanka 2001 Transparency International, 2002 Tajikistan 1999 Falkingham, 2000 Tajikistan 2001 Carasciuc, 2001 Thailand 1999 Phongpaichit, Treerat, Chaiyapong & Baker, 2000 Vietnam 1998 LSMS Survey Uzkbekistan 2001 FBS
4 Diseases of poverty and the 10/90 Gap Philip Stevens Introduction: What is the 10/90 Gap? Activists claim that only 10 per cent of global health research is devoted to conditions that account for 90 per cent of the global disease burden – the so-called ‘10/90 Gap’ (Medecins Sans Frontiers, 2001). They argue that virtually all diseases prevalent in low income countries are ‘neglected’ and that the pharmaceutical industry has invested almost nothing in research and development (R&D) for these diseases. Citing this alleged imbalance as justification, activists have for some years been calling for a complete redesign of the current R&D paradigm in order to ensure that more attention is paid to these ‘neglected diseases’ (Love & Hubbard, 2003). This could include measures such as an ‘essential research obligation’ that would require companies to reinvest a percentage of pharmaceutical sales into R&D for neglected diseases, either directly or through public R&D programs (Medecins Sans Frontiers, 2001), or the creation of a new public entity to direct R&D. This topic is now under discussion by a World Health Organisation working group following the report of its Commission on Intellectual Property, Innovation and Public Health. 1 But does such an imbalance really exist and what would be the effect of redesigning the R&D system? This chapter investigates the realities of the 10/90 gap and its relation to the diseases of poverty.
Page 1 and 2:
Fighting the Diseases of Poverty Ed
Page 3 and 4:
About International Policy Network
Page 5 and 6:
Fighting the Diseases of Poverty Ed
Page 8 and 9:
The authors Johan Biermann is a pla
Page 10:
The authors ix Maureen has publishe
Page 13 and 14:
xii Fighting the Diseases of Povert
Page 15 and 16:
xiv Fighting the Diseases of Povert
Page 17 and 18:
xvi Fighting the Diseases of Povert
Page 19 and 20:
xviii Fighting the Diseases of Pove
Page 21 and 22:
xx Fighting the Diseases of Poverty
Page 23 and 24:
xxii Fighting the Diseases of Pover
Page 25 and 26:
xxiv Fighting the Diseases of Pover
Page 27 and 28:
xxvi Fighting the Diseases of Pover
Page 29 and 30:
xxviii Fighting the Diseases of Pov
Page 31 and 32:
2 Fighting the Diseases of Poverty
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
2 South Africa’s healthcare under
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104: 74 Fighting the Diseases of Poverty
Page 129 and 130: 100 Fighting the Diseases of Povert
Page 153: 124 Fighting the Diseases of Povert
Page 205 and 206:
176 Fighting the Diseases of Povert
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 214 and 215:
6 Cost effective means of fighting
Page 216 and 217:
Cost effective means of fighting th
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
7 Counterfeit medicines in LDCs: pr
Page 234 and 235:
Counterfeit medicines in LDCs: prob
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
The value of vaccination 215 In the
Page 246 and 247:
The value of vaccination 217 the di
Page 248 and 249:
The value of vaccination 219 ◆
Page 250 and 251:
The value of vaccination 221 Figure
Page 252 and 253:
The value of vaccination 223 vaccin
Page 254 and 255:
The value of vaccination 225 moreov
Page 256 and 257:
The value of vaccination 227 encour
Page 258 and 259:
The value of vaccination 229 packag
Page 260 and 261:
The value of vaccination 231 longer
Page 262 and 263:
The value of vaccination 233 2005 t
Page 264 and 265:
The value of vaccination 235 long-t
Page 266 and 267:
The value of vaccination 237 Table
Page 268 and 269:
9 The World Health Organisation: a
Page 270 and 271:
The World Health Organisation: a ti
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
Notes Introduction 1 The UN Human D
Page 296 and 297:
Notes 267 18 The decline in their G
Page 298 and 299:
Notes 269 4 The diseases of poverty
Page 300 and 301:
Notes 271 to high-levels of researc
Page 302 and 303:
Notes 273 to register new products,
Page 304 and 305:
Notes 275 2 Snow, B et al., “The
Page 306 and 307:
Sources 277 Karoly, L., Greenwood,
Page 308 and 309:
Sources 279 ——— . 2004. The S
Page 310 and 311:
Sources 281 University, March 13. A
Page 312 and 313:
Sources 283 Alcazar, L and Andrade,
Page 314 and 315:
Sources 285 Di Tella, R. and Savedo
Page 316 and 317:
Sources 287 La Forgia, G. 2005. Hea
Page 318 and 319:
Sources 289 Shishkin, Sergey. 2003.
Page 320 and 321:
Sources 291 4 The diseases of pover
Page 322 and 323:
Sources 293 Wofford, D., & Shanahan
Page 324 and 325:
Sources 295 6 Cost effective means
Page 326 and 327:
Sources 297 7 Counterfeit medicines
Page 328 and 329:
The Campaign for Fighting Diseases
Page 330 and 331:
Dr. Henry I. Miller joined the Food
show all

Full text PDF - International Policy Network

Create successful ePaper yourself

Delete template?

Save as template?